2021-005602-10: Study which will investigate, if the treatment with Inclisiran, Bempedoic acid and monoclonal antibodies Alirocumab or Evolocumab has other than lipid-lowering effects such as change in platelet activity and inflammation markers. |
|
|
| Not yet recruiting | 3 | 60 | Europe | Inclisiran, Nilemdo, Repatha, Rosuvastatin, Atorvastatin, Solution for injection in pre-filled syringe, Film-coated tablet, Leqvio, Nilemdo, Repatha, Rosuvastatin, Atorvastatin | Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und vaskulären Biologie (ATVB), Verein zur Fördferung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und vaskulären Biologie (ATVB) | platelet activity and inflammation markers in patients with coronary artery disease, platelet activity and inflammation markers in patients with coronary artery disease, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Completed | 3 | 204 | US | lerodalcibep, LIB003, evolocumab, Repatha, alirocumab, Praluent | LIB Therapeutics LLC | Hypercholesterolemia, Cardiovascular Diseases | 09/22 | 12/22 | | |
EAST-aICAS, NCT06080256: Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis |
|
|
| Not yet recruiting | 3 | 80 | RoW | Alirocumab, Atorvastatin | The First Affiliated Hospital with Nanjing Medical University | Intracranial Atherosclerosis, Atherosclerotic Plaque, Stenosis | 12/24 | 12/24 | | |
| Recruiting | 3 | 140 | US | Alirocumab, Sar236553/REG727, Placebo | University of California, San Francisco, Massachusetts General Hospital | Dyslipidemias, Cardiovascular Diseases, HIV Infections | 07/24 | 07/25 | | |
